ArticleFrontiers in oncology2024

Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions.

Ping Yue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.